| scholarly article | Q13442814 |
| P2093 | author name string | Sanjay Singh | |
| Andre C Kalil | |||
| Alison G Freifeld | |||
| Pierre Fayad | |||
| Marcel P Devetten | |||
| Kim Bargenquast | |||
| Brandi Lesiak | |||
| David P Poage | |||
| P2860 | cites work | Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey | Q24570061 |
| Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases | Q24570064 | ||
| Clinical characteristics of the West Nile fever outbreak, Israel, 2000 | Q24644796 | ||
| Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice | Q27473398 | ||
| Clinical Findings of West Nile Virus Infection in Hospitalized Patients, New York and New Jersey, 2000 | Q27487807 | ||
| Efficacy of Interferon -2b and Ribavirin Against West Nile Virus In Vitro | Q27489383 | ||
| The outbreak of West Nile virus infection in the New York City area in 1999 | Q29618175 | ||
| West Nile encephalitis epidemic in southeastern Romania | Q29620822 | ||
| West Nile virus: a primer for the clinician | Q29620970 | ||
| Neurologic manifestations and outcome of West Nile virus infection | Q33967282 | ||
| Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study | Q34342278 | ||
| Viral hepatitis C. | Q35617324 | ||
| West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review | Q35764629 | ||
| Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions | Q35802787 | ||
| Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models | Q40505199 | ||
| Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis | Q40533997 | ||
| IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection | Q40551940 | ||
| Different pathogenicity of encephalitic togaviruses in organotypic cultures of spinal cord slices | Q42985612 | ||
| Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial | Q43049230 | ||
| Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration | Q48558650 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | West Nile virus | Q158856 |
| encephalitis | Q199615 | ||
| West Nile encephalitis | Q18555063 | ||
| P304 | page(s) | 764-766 | |
| P577 | publication date | 2005-02-07 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases | |
| P478 | volume | 40 |
| Q37708659 | A review of the epidemiological and clinical aspects of West Nile virus |
| Q37712155 | Acute flaccid paralysis due to West nile virus infection in adults: A paradigm shift entity |
| Q27472671 | Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival |
| Q40255394 | Arenavirus and West Nile virus in solid organ transplantation. |
| Q35138507 | Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease |
| Q42957459 | Cytomegalovirus induces interferon-stimulated gene expression and is attenuated by interferon in the developing brain. |
| Q36322125 | Development of effective therapies against West Nile virus infection |
| Q27484997 | Differential Effects of Mutations in NS4B on West Nile Virus Replication and Inhibition of Interferon Signaling |
| Q38211715 | Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features |
| Q37136479 | Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis |
| Q30250251 | Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen. |
| Q40986580 | Exogenous interferon prolongs survival of rabies infected mice. |
| Q36322559 | Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis |
| Q27487937 | Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man |
| Q95819383 | Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections |
| Q27484983 | Identification of Novel Small-Molecule Inhibitors of West Nile Virus Infection |
| Q38059915 | Immune evasion strategies of flaviviruses |
| Q27489865 | Innate immune evasion by hepatitis C virus and West Nile virus |
| Q37338989 | Interferons and their use in persistent viral infections |
| Q26699999 | Limited Effects of Type I Interferons on Kyasanur Forest Disease Virus in Cell Culture |
| Q37726746 | Measure and countermeasure: type I IFN (IFN-alpha/beta) antiviral response against West Nile virus |
| Q40281592 | Neglected infections of poverty in Texas and the rest of the United States: management and treatment options |
| Q40059267 | Neuroinvasive St. Louis Encephalitis Virus Infection in Solid Organ Transplant Recipients |
| Q26862449 | Novel approaches and challenges to treatment of central nervous system viral infections |
| Q27489893 | Progress on the development of therapeutics against West Nile virus |
| Q34482403 | Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts. |
| Q27472711 | Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus |
| Q60918413 | Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma |
| Q21284433 | Recent progress in West Nile virus diagnosis and vaccination |
| Q38047077 | Regulators of innate immunity as novel targets for panviral therapeutics |
| Q40457234 | Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. |
| Q37611829 | Targeting host factors to treat West Nile and dengue viral infections |
| Q40167373 | The first reported case of West Nile encephalitis in Korea |
| Q38772810 | The in vitro and in vivo antiviral properties of combined monoterpene alcohols against West Nile virus infection. |
| Q37982883 | The yin and yang of viruses and interferons |
| Q33926168 | Transgenic models for cytokine-induced neurological disease |
| Q34237824 | Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals |
| Q40228190 | West Nile Virus Infection in the Immunocompromised Patient |
| Q26865618 | West Nile Virus: biology, transmission, and human infection |
| Q56932479 | West Nile virus |
| Q61443836 | West Nile virus encephalitis in GATA2 deficiency |
| Q38074266 | West Nile virus infection and immunity |
| Q27486823 | Why the West in West Nile virus infections? |
| Q79157914 | [Antiviral therapy: from influenza to Pfeiffer's disease] |
Search more.